Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Edward Lee Carter: Provoked VTE May Not Tell the Whole Story About Recurrence Risk
Edward Lee Carter/LinkedIn
Sep 9, 2026, 13:02

Edward Lee Carter: Provoked VTE May Not Tell the Whole Story About Recurrence Risk

Edward Lee Carter, Clinical Pharmacist Practitioner at U.S. Department of Veterans Affairs, shared on LinkedIn:

“‘Provoked VTE‘ is a useful clinical label—but it may not tell us everything we need to know about future recurrence risk.

For years, a familiar framework has helped guide anticoagulation duration:

  • Provoked VTE: finite therapy
  • Unprovoked VTE: consider extended therapy

That framework remains useful. But the HI-PRO trial—and a recent Blood Advances commentary examining its implications—highlight an important gray zone:

What if the transient trigger resolves, but meaningful thrombotic risk remains?

HI-PRO enrolled 600 patients who had completed 3 months or longer of anticoagulation for VTE associated with a transient provoking factor and had 1 or more enduring risk factor.

Patients then received reduced-dose apixaban 2.5 mg twice daily or placebo for another 12 months.

The results were striking:

  • Recurrent symptomatic VTE: 1.3% vs 10.0%
  • HR 0.13 (95% CI 0.04–0.36)
  • Major bleeding: 1 patient vs 0
  • Clinically relevant nonmajor bleeding: 4.8% vs 1.7%

But context matters.

These were not typical low-risk patients with an isolated postoperative VTE. HI-PRO deliberately selected patients with enduring risk after a transiently provoked event. The trial was single-center and relatively small, and the population included a broad range of provoking and persistent risk factors.

So the lesson is not that every provoked VTE warrants longer anticoagulation.

It may be that the word ‘provoked’ should not end the risk assessment.

At diagnosis, identifying a provoking factor helps frame treatment. But that initial classification may not settle the duration question months later.

A major surgical trigger, a minor transient trigger, and a persistent prothrombotic condition do not necessarily carry the same implications for recurrence risk.

At reassessment, perhaps the better questions are:

  • What provoked the event?
  • Has that factor truly resolved?
  • What enduring risks remain?
  • What was the nature of the index VTE?
  • What is the patient’s current bleeding risk?
  • Does the balance still favor anticoagulation?

‘Provoked’ tells us something important about why the index event occurred.

It does not, by itself, define the patient’s future risk.

Duration of anticoagulation is not simply a label. It is a longitudinal clinical decision.”

Edward Lee Carter

Find more posts featuring Edward Lee Carter on Hemostasis Today.

Anticoagulation Blood Blood Advances Edward Lee Carter Health Hematology Hemostasis Hemostasis News Hemostasis Today HI-PRO Medicine Provoked VTE thrombosis venous thromboembolism VTE
NewsFeed